HempNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Unveils Medicinal Cannabis Division’s First Product Development Program

Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced the first product development program of the company’s newly created medicinal cannabis division, which will focus on the development of cannabinoids as a preventative treatment for anxiety disorders using PreveCeutical’s proprietary Sol-gel delivery platform. Per the update, the goal of the medical cannabis division’s program is to “create an effective therapy for anxiety that can be administered subtly and infrequently, addressing concerns of currently available treatments for anxiety disorders.” According to data from the Mayo Clinic, common approaches to treating anxiety, such as the prescription of selective serotonin reuptake inhibitors, are not always effective and are known to have numerous side effects, including insomnia, agitation and sexual dysfunction. Individuals who experience these issues could benefit greatly from PreveCeutical’s Sol-gel product development program.

To view the full press release, visit http://cnw.fm/uzFs2

About PreveCeutical Medical Inc.

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Program; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. This product is available on the company’s website. For more information, visit the company’s website at www.PreveCeutical.com

More from CannabisNewsBreaks

• HempNewsBreaks – Golden Triangle Ventures Inc. (OTC: GTVH) Restructures $7 Million in Legacy Debt, Secures Repurchase Option
• HempNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Positive Preclinical Results for INM-901 in Alzheimer’s Neuroinflammation Model
• HempNewsBreaks – CannabisNewsWire Named Official Newswire of 2025 Cannabis Means Business Expo in NYC 

About HempWire

HempWire (HW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) HempNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, HW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. HW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, HW brings its clients unparalleled visibility, recognition and brand awareness. HW is where news, content and information converge.

For more information please visit https://www.hempwire.com

Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.hempwire.com/disclaimer/

HempWire (HW)
Denver, Colorado
www.hempwire.com
303.498.7722 Office
Editor@HempWire.net